genOway / AXENIS: A new and exciting winner team

Posted by:

Read more...

Highlight AXENIS / CIPHE partnership: integrated know-how

Posted by:

Innovative murine models applied to                infectiology and immuno-oncology: humanized mice

The October the 4th 2017, the Inserm’s infrastructure division highlighted the activities of the Center for Immunophenomics (CIPHE, a joint Inserm service unit with CNRS and Aix-Marseille UMS 12 University, (Phenomin) based in Marseille and headed by Bernard Malissen and the AXENIS-spin off services company of Institut Pasteur and expert in the development ...

Read more...

Les Essentiels – Capital.fr – AXENIS

Posted by:

les-essentielles-capital-fr-axenisAXENIS

Pour des tests précliniques sécurisés et individualisés

Interview avec Erwan Corcuff DG

Read more...

« Informations Entreprises » Les PME à l’Heure Européenne: Souris humanisées, Des Traitements efficaces?

Posted by:

Les PME à l'heure européenne

AXENIS, acteur préclinique international, en immunologie et cancérologie.

AXENIS, Spin off de l’Institut Pasteur fondée en 2010, est une société de services utilisant des modèles murins humanisés comme modèles d’essais précliniques en immunologie et cancérologie, destinés à l’industrie pharmaceutique, les sociétés de biotechnologies, et la recherche publique.

Read more...

FAID 2016 – Interview with Erwan Corcuff (CEO)

Posted by:

FAID-Logo-2016-600pxIMG_1816

 

Read more...

« Le Monde » presents AXENIS as a talented start-up supported by Institut Pasteur. Interview with Mr Erwan Corcuff (CEO)

Posted by:

logo-lemonde
LA COURSE AUX TALENTS
Parmi les start-up incubées à l’Institut, Axenis, fondée en 2010, fabrique, pour les besoins de la recherche, des souris humanisées, en s’appuyant sur les travaux de ...
Read more...

AXENIS receives support from the EU (H2020 ‘SME Instrument’)

Posted by:

EU-flag_yellow_lowIn the context of the H2020 ‘SME Instrument’ program (Call: BIOTEC-5a-2014-1 – SME boosting biotechnology-based industrial processes driving competitiveness and sustainability), AXENIS has received support from the EU to develop its industrial capacity regarding its products and services.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 672027.

Project summary:

August 2013 / AXENIS and Arthrogen granted through the EUROSTARS program

Posted by:

AXENIS and Arthrogen granted through the EUROSTARS programA research program application designed by Arthrogen (Amsterdam, The Netherlands) and AXENIS (Paris, France) has been granted by the European EUROSTARS grant scheme. The TripleA-TP consortium will run for the coming 3 years and aims at validating a new humanized mouse model for applications in the field of human inflammation.

Read more...

Jul. 04, 2013 / Institut Pasteur becomes a shareholder of AXENIS

Posted by:

axenisAXENIS is pleased to announce that the Institut Pasteur is now part of the shareholders of company. This extends the already established partnership between the two entities.

Read more...

March 2013 / AXENIS and VALNEVA granted through the FUI program

Posted by:

AXENIS and VALNEVA granted through the FUI programA research program application designed by VALNEVA (Saint-Herblain, France) and AXENIS (Paris, France) has been granted by the French FUI (Fond Unique Inter-ministériel) grant scheme. The HUMAXIS consortium will run for the coming 4 years and aims at discovering new human monoclonal antibodies against human tumors.

Read more...
Page 1 of 2 12